1. Executive Summary
1.1 Influenza Vaccines Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research & Analysis Methods
2. Introduction to Influenza and its Treatment
2.1 What is Influenza?
2.2 What is the Social and Economic Burden?
2.3 Who are at Risk?
2.4 How does Influenza Spread?
2.5 Symptoms of Influenza
2.6 About the Influenza Virus
2.6.1 Antigenic Drift
2.6.2 Antigenic Shift
2.7 Seasonal Influenza Epidemic
2.8 How is Influenza Diagnosed?
2.9 Treatment of Influenza
2.9.1 Use of Antiviral Agents
2.9.2 Vaccination
2.9.2.1 Seasonal Influenza Vaccines
2.9.2.2 Pandemic Influenza Vaccines
2.9.2.3 'Pre-Pandemic' Influenza Vaccines
2.10 Types of Influenza Vaccine
2.10.1 Trivalent Inactivated Vaccines (TIV)
2.10.2 Trivalent Live Attenuated Influenza Vaccine (LAIV)
2.11 Methods of Vaccine Production
2.11.1 Egg-Based Manufacturing Technology
2.11.2 Cell-Based Manufacturing Technology
2.11.2.1 MCDK (Madin Darby Canine Kidney Cells)
2.11.2.2 Vero Cells
2.11.2.3 Per C6 Cells
2.11.3 Cell-Based Technique has an Edge over Egg-Based Vaccine Production
2.11.4 Steps Involved in Vaccine Production
2.11.5 Distribution of Vaccine
2.12 Influenza Pandemics - The New Threat
2.12.1 Increasing Global Vaccine Access to Combat Pandemic Influenza
2.12.2 Government Policy Regarding Pandemic Influenza Vaccines in the Mature Markets
3. The Influenza Vaccine Market - Global, Mature and Emerging
3.1 Challenges of the Global Influenza Vaccine Market
3.2 The Global Influenza Market Worth $4.3bn in 2009
3.3 The Global Market Projected to Grow to 2021
3.4 The Mature Market Projected to Maintain Steady Growth
3.5 The Emerging & Other Markets Projected to Expand Rapidly
3.6 The Growth Rate of the Emerging & Other Market Category Projected to be the Highest
4. Analysis of the Leading Players in the Influenza Vaccines Market
4.1 Influenza Vaccine Sales Estimate for Sanofi Pasteur
4.1.1 Fluzone/Vaxigrip
4.1.2 Investing in Building Capacity
4.2 Novartis Influenza Vaccines Sales to 2021
4.2.1 Fluvirin
4.3 GlaxoSmithKline PLC
4.3.1 GSK's Acquisition of ID Biomedical
4.3.2 Fluviral/FluLaval
4.3.3 Fluarix
4.3.4 Key Contracts Announced by GSK to Date
4.4 Other Manufacturers in the Mature Markets
4.4.1 Sales Forecasts for Influvac, Flumist and Inflexal
4.5 The Top Players are Building Global Manufacturing Capacities
4.6 The Key Players are Increasing Manufacturing Capacity in the Emerging Markets
5. Analysis of Mature Markets - the US, Japan, Germany, France, Italy, Spain and the UK
5.1 The Mature Market Predicted to Grow Steadily to 2021
5.1.1 Most of the Global Manufacturing Capacity is in the Developed Countries
5.2 EU5 - UK, Germany, France, Spain and Italy
5.2.1 Growth Rates of UK, Germany, France, Spain and Italy Predicted to Remain Steady
5.2.2 Vaccine Coverage Rates Differ Widely Across Target Groups and Countries in the EU
5.2.2.1 Strong Governmental Policies would Help to Achieve the WHO Objectives
5.2.2.2 The GP is at the Centre of the System in France
5.2.2.3 Increasing Influenza Vaccine Coverage: Funding for Regional Authorities in Italy
5.2.2.4 Enhancing Awareness in Germany
5.3 The United States
5.3.1 The Influenza Vaccines Market in the US is Expected to Grow to 2021
5.3.2 Sanofi Pasteur is the Market Leader in the US
5.3.3 Seasonal Influenza Vaccine Supply in US
5.3.4 Vaccine Coverage Rate in the US
5.3.4.1 Vaccine Coverage among Adults in the US
5.3.4.2 Favourable Reimbursement Schemes have Helped Increase Vaccination Rates
5.3.4.3 US Influenza Vaccine Prices Start to Drop
5.4 Japan
5.4.1 The Influenza Vaccine Market Expected to Grow in Japan
5.4.2 Low Vaccine Coverage Rates in Japan
5.4.3 Influenza Vaccine Prices in Japan
5.4.4 Regional Manufacturers Lead the Influenza Vaccine Market in Japan
6. Analysis of the Emerging Markets with Focus on China and India
6.1 An Overview
6.2 The Emerging Market Expected to Grow Significantly to 2021
6.3 China
6.3.1 Demographic Trends - Demand for Influenza Vaccines to Show Strong Growth
6.3.2 The Regulatory Environment in China is Complex
6.3.3 Vaccine Coverage Rates in China are Low
6.3.4 Key Players in the Chinese Market
6.3.5 Influenza Vaccine Sales Will Grow by 20% in China
6.4 India
6.4.1 Demographic Trends - Ageing Population in India to Grow by 15%
6.4.2 Merely 5% of GDP Spent on Healthcare System in India
6.4.3 High Incidence of Influenza among Children
6.4.4 Only a Small Amount of Drugs are Reimbursed in India
6.4.5 The Influenza Vaccine Market in India has Growth Potential
6.4.6 Key Constraints in the Influenza Vaccines Market in India
6.4.7 Influenza Vaccine Sales will Grow Significantly in India
6.4.8 Summary of Influenza Vaccine Sales in the Emerging Markets
7. Forces Affecting the Global Influenza Vaccines Market
7.1 SWOT Analysis of the Influenza Vaccines Market, 2010-2020
7.2 Influenza Vaccines: Manufacturers, International Health Agencies and Governments Show Commitment
7.3 Pandemic Preparedness
7.4 The Market has Weaknesses and Threats
7.5 Manufacturers Anxious about Strict and Lengthy Regulatory Procedures
7.6 The Anti-Vaccine Movement
7.6.1 Campaigns about Side-Effects of Vaccines
7.6.2 Controversy Surrounding Mercury-Containing Vaccines
7.6.3 Consequences of Anti-Vaccine Campaigns
7.7 Vaccines in the Developing World
7.7.1 Vaccine Distribution Networks and the Cold Chain
7.7.2 Vaccine Costs in Developing Countries
7.8 Pandemic Threats Create Demand for Vaccines
7.9 Towards a Universal Influenza Vaccine
7.10 Other Factors Influencing Growth in Influenza Market
7.10.1 Changing World Demographics
7.10.2 Population Increase
7.10.3 Emerging-Market Economies
8. R&D Pipeline Developments in the Influenza Vaccines Industry
8.1 Sanofi Pasteur
8.1.1 Increased Production Capacity of Fluzone
8.1.2 Influenza Vaccine Using PER.C6 Technology - Flucell
8.1.3 Novel Intradermal Delivery System - Flumicro
8.1.4 Universal Influenza A Recombinant Vaccine - ACAM Flu A
8.1.5 Pandemic Preparedness: Vaccine against H5N1 Virus (Avian Flu)
8.1.6 Pandemic Preparedness: Vaccine against H1N1 Virus (Swine Flu)
8.2 Novartis
8.2.1 Acquisition of Chiron - Optaflu Cell-Based Vaccine
8.2.2 Investigational Pre-Pandemic Vaccine AFLUNOV
8.2.3 Alliance with Intercell AG - Use of Next-Generation IC31 Adjuvant
8.2.4 Fluad MF59 Adjuvanted Influenza Vaccine More Efficacious than Non-Adjuvanted Influenza Vaccines in Children
8.2.5 Commitment to Pandemic Preparedness
8.2.6 FDA Approves Agriflu
8.3 GlaxoSmithKline PLC
8.3.1 Stockpile Initiative
8.3.2 Prepandrix - The H5N1 Prepandemic Vaccine
8.3.3 Late Phase Studies on New Generation Seasonal Influenza Vaccine
8.4 Other Vaccines in the Pipeline
8.5 Ongoing Studies on Vaccine Development
8.5.1 Universal Influenza Vaccine
8.5.2 Development of Novel Vaccine Delivery Systems
8.5.3 Pandemic Vaccine
8.5.4 Global Pandemic Influenza Action Plan (GAP) by the WHO
8.5.4.1 New Production Facilities
8.5.4.2 GAP Initiatives to Fund Influenza R&D
8.5.4.3 Constraints Faced by Research and Development
8.5.4.4 Steps Taken to Overcome Constraints
8.5.4.5 An Example of Technology Transfer in India
9. Experts' Views on Influenza Vaccines
9.1 Interview with Richard de Souza, CEO, Archimedes Pharma, and Dr Alan Smith, VP, R&D, Archimedes Development Limited
9.1.1 On the Constraints of Developing a Seasonal Influenza Vaccine
9.1.2 On the Principal Drivers and Restraints in the Influenza Vaccine Market
9.1.3 On Vaccination Coverage Rates in the Mature and Emerging Markets
9.1.4 On Important Pipeline Developments
9.1.5 On Vaccine Development in the Emerging Markets
9.1.6 On the Future of Influenza Vaccines
9.2 Interview with Catherine Ammon, World Heath Organization, Switzerland
9.2.1 On the Preparedness of Countries to Tackle a Pandemic
9.2.2 On the Current and Future Vaccination Rates
9.2.3 On the Most Important Unmet Need for Influenza Management
9.2.4 On the Principal Drivers and Restraints in the Vaccine Market
9.2.5 On the Common Seasonal Influenza Vaccines Used in Switzerland
9.2.6 On the Pipeline Vaccines with Most Promise
9.2.7 Other Comments on Influenza Vaccines and their Future
9.3 Interview with Professor David Bishai, MD, PhD, MPH, Department of Population, Family and Reproductive Health and International Health, Johns Hopkins University, USA
9.3.1 On Strategies for Presenting Vaccination to General Public
9.3.2 On Advantages and Disadvantages of MDVs and PFSs
9.3.3 On Pandemics Preparedness and Intervention
9.4 Interview with Wayne Rudolph, VP, Corporate Development. BiondVax Pharmaceuticals Ltd.
9.4.1 On Unmet Needs in Influenza Management
9.4.2 On the Principal Drivers and Restraints in the Influenza Market
9.4.3 On the Burden of Influenza Epidemics to the Economy
9.4.4 On Current Market for Influenza Vaccines
9.4.5 On Vaccination Rates in Mature and Emerging Markets
9.4.6 On Vaccine Development Capacity in US, EU and Emerging Markets
9.4.7 On BiondVax and Challenges of Developing a Universal Flu Vaccine
9.4.8 On BiondVax Technology for Vaccine Manufacture
9.4.9 On Progress of BiondVax' Universal Flu Vaccine
9.4.10 On R&D in Influenza Vaccines
9.4.11 Pipeline Products from BiondVax
9.4.12 Pipeline Products from Other Manufacturers
9.4.13 On Pandemic Preparedness
10. Conclusions
10.1 Influenza - More Dangerous than Generally Believed Previously
10.2 Vaccines - The Only Way to Contain the Spread
10.3 Influenza Vaccines - Demand vs. Supply
10.4 The Influenza Vaccine Market is Worth Over $4bn Worldwide
10.5 Sanofi Pasteur, GlaxoSmithKline and Novartis - the Top Three Companies in 2010
10.6 The Top Three Companies - Future Sales Growth Possible?
10.7 Future Outlook and Concluding Remarks
List of Tables
Table 2.1 Comparison between TIV and LAIV Technologies
Table 3.1 Global Distribution of Influenza Vaccine Sales ($bn & %), 2009 & 2021
Table 3.2 Projected Market Size ($bn) and Growth Rates (%) of the Global Influenza Vaccine Market, 2009-2015
Table 3.3 Projected Market Size ($bn) and Growth Rates (%) of the Global Influenza Vaccine Market, 2016-2021
Table 3.4 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets (US, Japan and EU5), 2009-2021
Table 3.5 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2009-2021
Table 4.1 Global Influenza Sales ($bn) and Market Shares (%) for Key Players, 2009, 2010, 2015 and 2021
Table 4.2 Key Mergers and Acquisitions in the Influenza Vaccines Market, 2005-2009
Table 4.3 Global Sales ($m) for Key Influenza Vaccine Producers, 2004, 2008 and 2009
Table 4.4 Global Sales ($m) for Leading Influenza Vaccine Products, 2009, 2010, 2015 and 2021
Table 4.5 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Sanofi Pasteur, 2009-2015
Table 4.6 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Sanofi Pasteur, 2016-2021
Table 4.7 Fluzone/Vaxigrip: Drivers and Restraints, 2009-2021
Table 4.8 Global Sales Forecast ($bn) and Growth Rates (%) for Fluzone/Vaxigrip, 2009-2015
Table 4.9 Global Sales Forecast ($m) and Growth Rates (%) for Fluzone/Vaxigrip, 2016-2021
Table 4.10 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Novartis, 2009-2015
Table 4.11 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Novartis, 2016-2021
Table 4.12 Fluvirin: Drivers and Restraints, 2010-2021
Table 4.13 Global Sales Revenues ($bn) and Growth Rates (%) for Fluvirin, 2009-2015
Table 4.14 Global Sales Revenues ($bn) and Growth Rates (%) for Fluvirin, 2016-2021
Table 4.15 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for GlaxoSmithKline, 2009-2015
Table 4.16 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for GlaxoSmithKline, 2016-2021
Table 4.17 Fluviral/FluLaval: Drivers and Restraints, 2010-2021
Table 4.18 Global Sales Revenues ($bn) and Growth Rates (%) for FluLaval/Fluviral, 2009-2015
Table 4.19 Global Sales Revenues ($bn) and Growth Rates (%) for FluLaval/Fluviral, 2016-2021
Table 4.20 Fluarix: Drivers and Restraints, 2010-2021
Table 4.21 Global Sales Revenues ($bn) and Growth Rates (%) for Fluarix, 2010-2015
Table 4.22 Global Sales Revenues ($bn) and Growth Rates (%) for Fluarix, 2016-2021
Table 4.23 Potential Worldwide Influenza Vaccine Manufacturers, 2010
Table 4.24 Other Key Influenza Vaccine Manufacturers in Mature Markets, 2010
Table 4.25 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Other Manufacturers, 2009-2015
Table 4.26 Global Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Other Manufacturers, 2016-2021
Table 4.27 Global Sales Revenues ($bn) and Growth Rates (%) for Influvac, Flumist and Inflexal, 2009-2015
Table 4.28 Global Sales Revenues ($bn) and Growth Rates (%) for Influvac, Flumist and Inflexal, 2016-2021
Table 4.29 Projected Global Manufacturing Capacities (Doses) for Key Players, 2012
Table 5.1 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets, 2009-2015
Table 5.2 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Mature Markets, 2016-2021
Table 5.3 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2009-2015
Table 5.4 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2016-2021
Table 5.5 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2009-2015
Table 5.6 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) for EU5 Countries, 2016-2021
Table 5.7 Vaccine Coverage Rates (%) in UK, Germany, France, Spain and Italy, 2008-2009
Table 5.8 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) in the US, 2009-2015
Table 5.9 Influenza Vaccine Sales Revenues ($m) and Growth Rates (%) in the US, 2016-2021
Table 5.10 Top Flu Vaccine Suppliers in the US for the 2008-2009 Season
Table 5.11 Influenza Vaccine Coverage among Adults in the US, 2004-2005
Table 5.12 Influenza Vaccine Coverage among Children in the US, 2004-2005
Table 5.13 Paediatric Influenza Vaccine Price ($) List (May 1, 2009)
Table 5.14 Adult Influenza Vaccines Price ($) List (May 1, 2009)
Table 5.15 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in Japan, 2009-2015
Table 5.16 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in Japan, 2016-2021
Table 5.17 Influenza Vaccine Price ($) per Unit in Japan, 2009-2021
Table 6.1 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2009-2015
Table 6.2 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) for Emerging & Other Markets, 2016-2021
Table 6.3 Leading Influenza Vaccine Manufacturers in Emerging & Other Markets, 2010
Table 6.4 Demographic Statistics for China, 2010
Table 6.5 Estimated Number of Vaccinated People in China, 2009, 2012, 2016 and 2021
Table 6.6 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in China, 2009-2015
Table 6.7 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in China, 2016-2021
Table 6.8 Demographic Statistics for India, 2009
Table 6.9 Estimated Number of Vaccinated People in India, 2010-2021
Table 6.10 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in India, 2009-2015
Table 6.11 Influenza Vaccine Sales Revenues ($bn) and Growth Rates (%) in India, 2016-2021
Table 6.12 Summary of Influenza Vaccine Sales Revenues ($bn) and Growth Rate (%) in Emerging & Other Markets, 2009-2021
Table 7.1 SWOT Analysis: Strengths and Weaknesses of the Global Influenza Vaccines Market, 2011-2021
Table 7.2 SWOT Analysis: Opportunities and Threats in the Global Influenza Vaccines Market, 2011-2021
Table 7.3 Influenza Vaccines Deals and Alliances: Some Recent Examples between Major Pharmaceutical Producers and Companies in Emerging & Other Markets, 2010
Table 8.1 Key Cell-Culture Influenza Vaccines, 2010
Table 8.2 Influenza Vaccine Pipeline for Sanofi Pasteur, 2010
Table 8.3 Influenza Vaccine Pipeline for Novartis, 2010
Table 8.4 Paediatric Influenza Vaccine Pipeline for GlaxoSmithKline, 2010
Table 8.5 Other Influenza Vaccines: Pipeline for GlaxoSmithKline, 2010
Table 8.6 Late-Stage (Registered) Influenza Vaccine Pipeline, 2010
Table 8.7 Mid-Stage (Phase II & III) Influenza Vaccine Pipeline, 2010
Table 8.8 Early-Stage (Phase I) Influenza Vaccine Pipeline, 2010
Table 8.9 Discovery-Stage Influenza Vaccine Pipeline, 2010
Table 8.10 Preclinical-Stage Influenza Vaccine Pipeline, 2010
List of Figures
Figure 2.1 Socio-Economic Burden of Influenza
Figure 2.2 Types of Influenza A Virus
Figure 2.3 Steps Involved in Vaccine Production
Figure 3.1 Global Distribution of Influenza Vaccine Sales (%), 2009
Figure 3.2 Distribution of Influenza Vaccine Sales (%) in Top Five EU Markets, 2009
Figure 3.3 Global Distribution of Influenza Vaccine Sales (%), 2021
Figure 3.4 Distribution of Influenza Vaccine Sales (%) in Top Five EU Markets, 2021
Figure 3.5 Influenza Vaccine Sales Revenues ($bn) for the Global Market, 2009-2021
Figure 3.6 Influenza Vaccine Sales Revenues ($bn) for Mature Markets (US, Japan and EU5), 2009-2021
Figure 3.7 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2009-2021
Figure 4.1 Global Influenza Vaccine Market Shares (%) for Key Players, 2009
Figure 4.2 Global Influenza Vaccine Market Shares (%) for Key Players, 2010
Figure 4.3 Global Influenza Vaccine Market Shares (%) for Key Players, 2015
Figure 4.4 Global Influenza Vaccine Market Shares (%) for Key Players, 2021
Figure 4.5 Global Sales ($m) for Leading Influenza Vaccine Producers, 2004, 2008 and 2009
Figure 4.6 Global Market Shares (%) for Leading Influenza Vaccine Products, 2009
Figure 4.7 Global Market Shares (%) for Leading Influenza Vaccine Products, 2010
Figure 4.8 Global Market Shares (%) for Leading Influenza Vaccine Products, 2015
Figure 4.9 Global Market Shares (%) for Leading Influenza Vaccine Products, 2021
Figure 4.10 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Sanofi Pasteur, 2010-2015
Figure 4.11 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Sanofi Pasteur, 2016-2021
Figure 4.12 Global Sales Revenues ($bn) for Fluzone/Vaxigrip, 2009-2015
Figure 4.13 Global Sales Revenues ($bn) for Fluzone/Vaxigrip, 2016-2021
Figure 4.14 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Novartis, 2009-2015
Figure 4.15 Global Influenza Vaccine Sales Revenues ($bn) and Market Shares (%) for Novartis, 2016-2021
Figure 4.16 Global Sales Revenues ($bn) and Market Shares (%) for Fluvirin, 2009-2015
Figure 4.17 Global Sales Revenues ($bn) and Market Shares (%) for Fluvirin, 2016-2021
Figure 4.18 Global Sales Revenues ($bn) and Market Shares (%) for GlaxoSmithKline, 2009-2015
Figure 4.19 Global Sales Revenues ($bn) and Market Shares (%) for GlaxoSmithKline, 2016-2021
Figure 4.20 Global Sales Revenues ($bn) and Market Shares (%) for FluLaval/Fluviral, 2009-2015
Figure 4.21 Global Sales Revenues ($bn) and Market Shares (%) for FluLaval/Fluviral, 2016-2021
Figure 4.22 Global Sales Revenues ($bn) and Market Shares (%) for Fluarix, 2009-2015
Figure 4.23 Global Sales Revenues ($bn) and Market Shares (%) for Fluarix, 2016-2021
Figure 4.24 Global Sales Revenues ($bn) and Market Shares (%) for Other Manufacturers, 2009-2015
Figure 4.25 Global Sales Revenues ($bn) and Market Shares (%) for Other Manufacturers, 2016-2021
Figure 4.26 Global Sales Revenues ($bn) for Influvac, Flumist and Inflexal, 2009-2021
Figure 4.27 Global Manufacturing Capacities (Doses) for Key Players, 2009
Figure 4.28 Projected Global Manufacturing Capacities (Doses) for Key Players, 2012
Figure 5.1 Influenza Vaccine Sales Revenues ($bn) for Mature Markets (US, Japan and EU5), 2009-2021
Figure 5.2 Average Vaccine Prices for the Mature Markets, 2009-2021
Figure 5.3 WHO Revenues for Global Seasonal Influenza Vaccine Manufacturing Capacity, 2009
Figure 5.4 Influenza Vaccine Sales Revenues ($bn) for the EU5 Markets, 2009-2021
Figure 5.5 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2009-2021
Figure 5.6 Influenza Vaccine Sales Revenues ($m) in the US, 2009-2021
Figure 5.7 Influenza Vaccine Market Shares (%) in the US, 2007-2008
Figure 5.8 Influenza Vaccine Market Shares (%) in the US, 2008-2009
Figure 5.9 Influenza Vaccine Production and Distribution for the US Market, 2000-2008
Figure 5.10 Average US Influenza Vaccines CDC Prices ($), 2002-2009
Figure 5.11 Influenza Vaccine Sales Revenues ($bn) in Japan, 2009-2021
Figure 5.12 Movement of Average Influenza Vaccine Price ($) per Unit in Japan, 2010-2021
Figure 6.1 Influenza Vaccine Sales Revenues ($bn) for Global, Mature and Emerging & Other Markets, 2010-2021
Figure 6.2 Influenza Vaccine Sales Revenues ($bn) in China, 2009-2021
Figure 6.3 Influenza Vaccine Sales Revenues ($bn) in India, 2009-2021
Figure 6.4 Summary of Influenza Vaccine Sales Revenues ($bn) in Emerging & Other Markets, 2009-2021
Figure 9.1 Crude Death Rate (CDR) in England, 1500-2000